Targeting cell cycle kinases and kinesins in anticancer drug development.
about
Emerging molecular classifications and therapeutic implications for gastric cancerPhase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer.
P2860
Targeting cell cycle kinases and kinesins in anticancer drug development.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Targeting cell cycle kinases and kinesins in anticancer drug development.
@en
Targeting cell cycle kinases and kinesins in anticancer drug development.
@nl
type
label
Targeting cell cycle kinases and kinesins in anticancer drug development.
@en
Targeting cell cycle kinases and kinesins in anticancer drug development.
@nl
prefLabel
Targeting cell cycle kinases and kinesins in anticancer drug development.
@en
Targeting cell cycle kinases and kinesins in anticancer drug development.
@nl
P2093
P2860
P356
P1476
Targeting cell cycle kinases and kinesins in anticancer drug development.
@en
P2093
L Rhoda Molife
Sarah P Blagden
Timothy A Yap
P2860
P304
P356
10.1517/17460441.2.4.539
P407
P577
2007-04-01T00:00:00Z